Emera TSE: EMA reported third-quarter adjusted earnings of C$260 million and outlined a C$21.5 billion, five-year capital plan, with most of the investment directed to its Florida utilities.
Emera's regulated asset base expanded roughly 21% from $24.5B to $29.6B in net PPE between 2024Q3 and 2026Q3, yet equity grew only to $14.4B, suggesting capital expansion is increasingly debt-funded with total debt reaching $21.6B.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Quarterly margins swung widely, from a 34.6% operating margin in 2025Q1 to 10.5% in 2025Q4, while the 2026Q3 net margin of 10.2% on $2.0B revenue suggests earnings remain timing-sensitive rather than steadily compounding.
Emera has filed materials detailing a C$20 billion capital plan for 2026, which is expected to drive growth and enhance operational capabilities. This significant investment could position the company favorably in the energy sector.
The consensus rating for Emera among Wall Street analysts is 'Moderate Buy,' with a notable number of analysts recommending a buy. This positive sentiment reflects confidence in the company's future performance.
Overall, technical signals for Emera indicate a 'Strong Buy' candidate evaluation, with the stock trading above the Exponential Moving Average (EMA). This trend suggests bullish momentum and potential for continued price appreciation.
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | $0.60-3.7% vs $0.62 | $1.4B-0.7% vs $1.4B |
Q3 2026 Aug 7, 2026 | $0.49-2.2% vs $0.50 | $1.4B+5.4% vs $1.3B |
Q2 2026 May 8, 2026 | $0.98+13.7% vs $0.87 | $2.0B+16.1% vs $1.7B |
Q1 2026 Feb 23, 2026 | $0.40-3.9% vs $0.42 | $1.5B+28.5% vs $1.1B |
Emera TSE: EMA reported third-quarter adjusted earnings of C$260 million and outlined a C$21.5 billion, five-year capital plan, with most of the investment directed to its Florida utilities.
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced positive topline results from the pivotal Phase 3 ECLIPSE 1 trial evaluating monthly subcutaneous adminis
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced new, expanded data from the Phase 2 SOLSTICE trial evaluating monthly subcutaneous administration of eleb
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today, November 6, 2026, Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 third quarter financial results and 5-year capital and funding plans1. Third Quarter & Five-Year Capital Plan Highlights Reported Q3 2026 adjusted EPS2 of $0.85 and reported EPS of $0.59. Introduced five-year, $21.5 billion capital plan3, expected to drive 7.5%-8.5% rate base growth through 20314, with ~82% of planned investment in Florida5 to support customer demand. Increased.
Benchmark EMA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Emera Incorporated (EMA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $51.54 | $15.77B | 22.80 | 15.31% | 11.8% | 7.62% | 2.61% | |
| $14.97 | $10.68B | 5.86 | -0.37% | 13.46% | 15.23% | 4.7% | |
| $107.57 | $50.2B | 24.72 | 8.98% | 14.71% | 11.26% | 2.22% | |
| $35.19 | $26.48B | 20.21 | 6.85% | 13.62% | 8.74% | 3.03% | |
| $87.04 | $20.06B | 19.38 | 1.65% | 16.7% | 10.18% | 3.02% | |
| $102.87 | $12.47B | 19.35 | 4.2% | 11.59% | 9.18% | 3.37% |
Emera Incorporated (EMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when EMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Emera Incorporated (EMA) stock FAQ — growth, dividends, profitability & financials explained
Emera Incorporated (EMA) reported $8.46B in revenue over the trailing twelve months. Revenue was $8.30B in fiscal year 2025. That is 907% more than the $824.6M of fiscal year 1999.
Emera Incorporated (EMA) revenue fell by 0.9% over the trailing twelve months, compared with the twelve months before.
Yes. Emera Incorporated (EMA) earned $997.5M in net income over the trailing twelve months (a 11.8% net margin).
Yes. Emera Incorporated (EMA) pays a dividend that yields 2.61% at the current price, a moderate yield.
Emera Incorporated (EMA) had a return on equity (ROE) of 7.6% over the trailing twelve months. That is below the market's typical 10-15%.
Emera Incorporated (EMA) had negative free cash flow of $1.03B over the trailing twelve months.
Emera Incorporated (EMA) has a dividend payout ratio of 53%. This suggests the dividend is well-covered and sustainable.